PortfoliosStock ScreensStocksStockXcel

Immix Biopharma Inc.

IMMX | US

8.37

USD

-0.85

-9.27%

IMMX | US

About Immix Biopharma Inc.

Sector

Healthcare

Industry

Biotechnology

Earnings date

30/06/2024

As of date

02/06/2026

Close

8.37

Open

9.20

High

9.34

Low

8.23

Immix Biopharma Inc. a clinical-stage biopharmaceutical company engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111 a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120 a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles California.

View Less

IMMX | US

Risk
71.7
Sharpe
2.91
Luna's Score
52/100
Recommendation
Hold

Luna says (IMMX | US)

What's Working

Low Market Beta (-0.4 to 0.8)

Low Debt to Equity (< 0.25)

Low Debt to Asset (< 0.2)

Value Stock (Price to Book < 3)

Strong Sharpe Ratio (> 1.2)

What's not Working

Negative Momentum (Declining Price)

Weakness based on declining price with high volume

Price Below SMA10D

High 6-Month Volatility (>65%)

Microcap (<300M USD)

Volatility Signals

Bearish: Increased Volatility (6-month > 1-month volatility)

Risk Meter

10 days

55.0%

1 month

71.7%

3 months

80.0%

6 months

86.7%

Returns

Fundamental Ratios

PE

-

Fwd. PE

-

Price to book

1.98

Debt to equity

0.05

Debt to assets

0.04

Ent. to EBITDA

-0.37

Ent. to rev.

-

PEG

-

Other Fundamentals

EBITDA

-20.18M

MarketCap

229.62M

MarketCap(USD)

229.62M

Div. yield

-

Op. margin

-

Erngs. growth

-

Rev. growth

-

Ret. on equity

-103.81

Short ratio

6.35

Short perc.

6.44

Market Sentiment (SMA and Price signals)

Short-term: Bearish (SMA10D < SMA1M)

Intermediate-term: Bearish (SMA1M < SMA3M)

Long-term: Bullish (SMA6M > SMA12M)

SMAs: Stock Price Trends

Range10D

1.76

Range1M

2.77

Range3M

3.71

Volumes: Market Activity

Rel. volume

1.01

Price X volume

11.52M

Peers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
Verrica Pharmaceuticals IncVRCABiotechnology5.79247.05M-1.86%n/a-348.20%
Entrada Therapeutics Inc. Common StockTRDABiotechnology6.64247.01M-3.91%5.7714.99%
DiaMedica Therapeutics IncDMACBiotechnology5.77246.65M-1.20%n/a0.73%
Abeona Therapeutics IncABEOBiotechnology5.69246.46M1.07%n/a31.63%
CytomX Therapeutics IncCTMXBiotechnology3.16242.67M-8.41%7.73-37.61%
AC Immune SAACIUBiotechnology2.42239.44M-1.63%n/a0.00%
LogicBio Therapeutics IncLOGCBiotechnology9.04237.52M-0.11%n/a0.00%
Anavex Life Sciences CorpAVXLBiotechnology2.785236.16M-6.54%n/a0.00%
Editas Medicine IncEDITBiotechnology2.82232.58M-15.57%n/a16.68%
Shattuck Labs IncSTTKBiotechnology4.87232.43M-13.81%n/a3.45%
  • 1

Diversifiers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
Urban One IncUONEKBroadcasting - Radio4.7249.14M-10.36%n/a268.43%
CPI Card Group IncPMTSBuilding Products & Equipment16.74186.78M-0.42%15.61-621.78%
ONEWATER MARINE INC.ONEWRecreational Vehicles11.36182.41M2.53%n/a286.96%
Kewaunee Scientific CorporationKEQUBuilding Products & Equipment40.57116.51M-0.44%5.1619.82%
Virco Mfg. CorporationVIRCBuilding Products & Equipment6.0197.90M0.84%9.0939.79%
Twin Vee PowerCats Co. Common StockVEEERecreational Vehicles7.0967.49M2.75%n/a19.98%
ILAGILAGBuilding Products & Equipment3.601665.04M-4.21%n/a5.48%
Saga Communications IncSGABroadcasting - Radio9.3758.67M-0.64%14.487.10%
Beasley Broadcast Group IncBBGIBroadcasting - Radio19.5929.83M25.34%n/a204.46%
Antelope Enterprise Holdings LimitedAEHLBuilding Products & Equipment1.1116.22M-2.63%0.0316.03%
  • 1

Industry Comparison

ParameterCompanyIndustryIndicator
Enterprise to EBITDA-0.37-Cheaper
Ent. to Revenue---
PE Ratio-41.03-
Price to Book1.9815.55Cheaper
Dividend Yield---
Std. Deviation (3M)80.02-Par
Debt to Equity0.05-1.23Expensive
Debt to Assets0.040.25Cheaper
Market Cap229.62M-Emerging
  • 1

Unlock Your Investing Potential

Register with Xstocks

Join over 2,000+ Investors

Register now and embark on your journey to informed and successful investing.

Explore Industry Correlations

Explore Industry Correlations

Uncover Trading and Hedging Opportunities

Gain valuable insights into potential trading opportunities and discover strategic hedging possibilities

Discover Top-Performing Industries

Discover Top performing Industries

Explore Stocks for Short and Long-Term Gains

Uncover opportunities at both short-term and long-term horizons, allowing you to make informed investment decisions.

Follow us @XStocks007